Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • dcgi

    Tag: dcgi

    You Searched For "dcgi"
    Torrent Pharma, Glenmark enter agreement to market Remogliflozin under trademark Zucator in India

    Torrent Pharma, Glenmark enter agreement to market Remogliflozin under trademark Zucator in India

    Medical Dialogues Bureau11 July 2019 10:00 AM IST
    "Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark 'Zucator' in India," Glenmark Pharma...
    Procedure for approval of FDC drugs: CDSCO releases notification; Details

    Procedure for approval of FDC drugs: CDSCO releases notification; Details

    Meghna A Singhania24 May 2019 6:12 PM IST
    New Delhi: Through a recent notification, the Central Drugs Standard Control Organization (CDSCO) has directed drug manufacturers and all the...
    Drug Alert: CDSCO declares 31 samples as sub-standard in quality in random sampling; Details

    Drug Alert: CDSCO declares 31 samples as sub-standard in quality in random sampling; Details

    Meghna A Singhania21 May 2019 4:44 PM IST
    New Delhi: Apex drug regulatory body, the Central Drugs Standard Control Organization (CDSCO) has declared more than a dozen drugs as sub-standard in...
    Adverse Reactions: Cefotaxime, Oflaxicin, Cefixime told to carry Warning by CDSCO

    Adverse Reactions: Cefotaxime, Oflaxicin, Cefixime told to carry Warning by CDSCO

    Meghna A Singhania17 April 2019 12:26 PM IST
    New Delhi: The national regulatory body for Indian Pharmaceutical and Medical Device, Central Drugs Standard Control Organisation (CDSCO) has ordered...
    FDC Rationality: Now 6 months accelerated stability study data to be submitted, directs DCGI

    FDC Rationality: Now 6 months accelerated stability study data to be submitted, directs DCGI

    Meghna A Singhania27 March 2019 4:48 PM IST
    New Delhi: Manufacturers of Fixed Dose Combinations drugs ( FDC drugs) which have declared rational and approved by Drugs Controller General India...
    Setback to Meril Lifesciences MeRess100: NPPA refuses to give relief of price cap exemption for the biodegradable stent

    Setback to Meril Lifesciences MeRess100: NPPA refuses to give relief of price cap exemption for the biodegradable stent

    Meghna A Singhania5 March 2019 5:01 PM IST
    New Delhi: In a major setback to Meril Lifesciences, the drug price regulator National Pharmaceutical Pricing Authority(NPPA) has refused to give it...
    J&J passes asbestos test, allowed to make baby powder in India

    J&J passes asbestos test, allowed to make baby powder in India

    Farhat Nasim1 March 2019 2:28 PM IST
    NEW DELHI: In a major relief to Johnson & Johnson(J&J), no asbestos was found in the baby powder manufactured in Baddi and Mulund plants. The...
    NPPA to decide on Merrills Request for price cap exemption for its biodegradable stent

    NPPA to decide on Merrills Request for price cap exemption for its biodegradable stent

    Meghna A Singhania3 Feb 2019 11:16 AM IST
    New Delhi: A Year after Abbott's launch of biodegradable stents which was later withdrawn globally, Meril Life Sciences has moved the National...
    Johnson & Johnson talc issue: NGO writes to National Human Rights Commission

    Johnson & Johnson talc issue: NGO writes to National Human Rights Commission

    Medical Dialogues Bureau25 Dec 2018 9:35 AM IST
    The NGO has said that it has sought to draw the "urgent attention" of the rights panel, towards the relevance of the report on the baby talc powder...
    Another trouble for J&J: CDSCO seize samples of baby products for testing

    Another trouble for J&J: CDSCO seize samples of baby products for testing

    Farhat Nasim22 Dec 2018 12:14 PM IST
    The action by CDSCO has come at a time when the company is already embroiled in a controversy over its faulty hip implants. New Delhi: Following...
    CDSCO tightens safety and labelling rules for ISOTRETINOIN,prescription of dermatologist mandatory

    CDSCO tightens safety and labelling rules for ISOTRETINOIN,prescription of dermatologist mandatory

    Farhat Nasim21 Dec 2018 1:06 PM IST
    In light of concerns raised regarding Isotretinoin, the matter has been examined by CDSCO in consultation with the Subject Expert Committee...
    Final regulations on e pharmacy likely by December-end, says DCGI

    Final regulations on e pharmacy likely by December-end, says DCGI

    Farhat Nasim8 Dec 2018 10:29 AM IST
    In September, the Union health ministry came out with draft rules on the sale of drugs by e pharmacies. Panaji: The union government is expected to...
    PrevNext

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok